DeVries A, Semchuk W M, Betcher J G
Department of Pharmacy, Plains Health Centre, Regina, Saskatchewan, Canada.
Pharmacotherapy. 1998 May-Jun;18(3):581-7.
We conducted a critical review of the literature on ketoconazole in preventing acute respiratory distress syndrome (ARDS), a serious disorder associated with high mortality. Two double-blind, prospective, placebo-controlled, randomized trials compared ketoconazole with placebo for prophylaxis of ARDS. In one trial, compared with placebo, ketoconazole resulted in a reduced frequency of ARDS (6% vs 31%, p<0.01), lower plasma thromboxane B2 levels (33 vs 75 pg/ml, p<0.05), and shorter intensive care unit stay (7 vs 15.5 days, p<0.05). In the second trial the drug reduced the frequency of ARDS (15% vs 64%, p=0.002), lowered thromboxane B2 levels (83 vs 143 pg/ml), and reduced mortality (15% vs 39%, p=0.05) compared with placebo. Larger multicenter studies are warranted to validate the findings of these two trials.
我们对酮康唑预防急性呼吸窘迫综合征（ARDS）的文献进行了批判性综述，ARDS是一种死亡率很高的严重疾病。两项双盲、前瞻性、安慰剂对照、随机试验比较了酮康唑与安慰剂预防ARDS的效果。在一项试验中，与安慰剂相比，酮康唑使ARDS的发生率降低（6%对31%，p<0.01），血浆血栓素B2水平降低（33对75 pg/ml，p<0.05），重症监护病房住院时间缩短（7对15.5天，p<0.05）。在第二项试验中，与安慰剂相比，该药物降低了ARDS的发生率（15%对64%，p=0.002），降低了血栓素B2水平（83对143 pg/ml），并降低了死亡率（15%对39%，p=0.05）。有必要进行更大规模的多中心研究来验证这两项试验的结果。
